Hemostemix (CVE:HEM) Shares Up 29.4% – What’s Next?

by · The Markets Daily

Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 29.4% during trading on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. Approximately 602,760 shares traded hands during mid-day trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Trading Up 29.4%

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market capitalization of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25. The business’s 50-day moving average is C$0.09 and its two-hundred day moving average is C$0.10.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Further Reading